IPCA Laboratories Ltd unveiled Diulcus®, a solution designed to tackle Diabetic Foot Ulcer (DFU) challenges in India. Developed by NovaLead Pharma Pvt Ltd, a known name in drug repurposing, Diulcus® signifies a major leap forward in DFU management.
The product has gained approval from the Central Drugs Standard Control Organization (CDSCO) and received partial funding from the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India initiative.
As reported by theweek.in, during phase three trials conducted in India, Diulcus® showcased impressive results, achieving a 60.3% ulcer closure rate within three months.
Remarkably, patients maintained a 77.20% closure rate over six months, even after discontinuing treatment at three months. These outcomes represent some of the highest success rates for DFU treatments to date.
Ajit Jain, Managing Director, IPCA Laboratories Ltd said, “With more than 15% of diabetic patients experiencing DFU at least once in their lives, DFU stands as a leading complication of chronic diabetes. The approval of this innovative repurposed drug is pivotal, given that DFU is a major cause of lower limb amputations worldwide. We are thrilled to collaborate with NovaLead Pharma Pvt Ltd through an IP licensing agreement to introduce Diulcus® to DFU patients in India. This initiative underscores IPCA’s dedication to addressing unmet medical needs and advancing diabetes care”.